← Leaderboards
Liudmila Cebotaru
Johns Hopkins University
$6,044,233
Attributed
$7,721,269
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,721,269 · 4
By mechanism
R01$7,721,269 · 4
Top collaborators
- William B. Guggino5 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Garry R Cutting$22,692,645
- Anirban Maitra$50,247,714
- Feng Qian$9,105,940
- Michael G. Goggins$19,822,981
- William B. Guggino$17,014,421
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsMutationCystic Fibrosis PatientsMortalityDesignMorbidity - Disease RateGenesCystic Fibrosis Transmembrane Conductance RegulatorPhenotypeCystic FibrosisOrganBaseAffectNovel TherapeuticsResponseBeta ActinPromoterMutantAdeno-Associated Viral VectorNovel StrategiesChickensClinical TrialsGene TherapyDose
Grant awards (15)
Cystic Fibrosis Gene Therapy with adeno-associated viral vectors$811,873
R01 · FY2025 · HL · contact PI
Cystic Fibrosis Gene Therapy with adeno-associated viral vectors$818,734
R01 · FY2024 · HL · contact PI
Developing a New Therapeutic Approach for Autosomal Dominant Polycystic Kidney Disease.$345,840
R01 · FY2024 · DK · contact PI
Developing a New Therapeutic Approach for Autosomal Dominant Polycystic Kidney Disease.$360,250
R01 · FY2023 · DK · contact PI
Rescue of multiorgan pathophysiology by adeno-associated virus 1 gene therapy$409,375
R01 · FY2022 · DK · contact PI
Developing a New Therapeutic Approach for Autosomal Dominant Polycystic Kidney Disease.$360,250
R01 · FY2022 · DK · contact PI
Rescue of multiorgan pathophysiology by adeno-associated virus 1 gene therapy$409,375
R01 · FY2021 · DK · contact PI
Developing a New Therapeutic Approach for Autosomal Dominant Polycystic Kidney Disease.$360,250
R01 · FY2021 · DK · contact PI
CF Gene Therapy with adeno-associated viral vectors$726,898
R01 · FY2020 · HL · contact PI
Developing a New Therapeutic Approach for Autosomal Dominant Polycystic Kidney Disease.$360,250
R01 · FY2020 · DK · contact PI
Developing a New Therapeutic Approach for Autosomal Dominant Polycystic Kidney Disease.$131,000
R01 · FY2020 · DK · contact PI
CF Gene Therapy with adeno-associated viral vectors$723,820
R01 · FY2019 · HL · contact PI
CF Gene Therapy with adeno-associated viral vectors$723,820
R01 · FY2018 · HL · contact PI
CF Gene Therapy with adeno-associated viral vectors$664,618
R01 · FY2017 · HL · contact PI
CF Gene Therapy with adeno-associated viral vectors$514,916
R01 · FY2016 · HL · contact PI